加拿大蒙特利尔大学Daniel E. Kaufmann、美国洛克菲勒大学Michel C. Nussenzweig等研究人员合作发现,抗HIV-1抗体联用疗法与病毒特异性T细胞免疫增加相关。2020年2月3日,《自然—医学》在线发表了这项成果。
Title: Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity
Author: Julia Niessl, Amy E. Baxter, Pilar Mendoza, Mila Jankovic, Yehuda Z. Cohen, Allison L. Butler, Ching-Lan Lu, Mathieu Dub, Irina Shimeliovich, Henning Gruell, Florian Klein, Marina Caskey, Michel C. Nussenzweig, Daniel E. Kaufmann
Issue&Volume: 2020-02-03
Abstract: Combination antiretroviral therapy (ART) is highly effective in controlling human immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a latent viral reservoir1,2. Potent broadly neutralizing antibodies (bNAbs) represent a potential alternative or adjuvant to ART. In addition to suppressing viremia, bNAbs may have T cell immunomodulatory effects as seen for other forms of immunotherapy3. However, this has not been established in individuals who are infected with HIV-1. Here, we document increased HIV-1 Gag-specific CD8+ T cell responses in the peripheral blood of all nine study participants who were infected with HIV-1 with suppressed blood viremia, while receiving bNAb therapy during ART interruption4. Increased CD4+ T cell responses were detected in eight individuals. The increased T cell responses were due both to newly detectable reactivity to HIV-1 Gag epitopes and the expansion of pre-existing measurable responses. These data demonstrate that bNAb therapy during ART interruption is associated with enhanced HIV-1-specific T cell responses. Whether these augmented T cell responses can contribute to bNAb-mediated viral control remains to be determined.
DOI: 10.1038/s41591-019-0747-1
Source: https://www.nature.com/articles/s41591-019-0747-1
Nature Medicine:《自然—医学》,创刊于1995年。隶属于施普林格·自然出版集团,最新IF:30.641
官方网址:https://www.nature.com/nm/
投稿链接:https://mts-nmed.nature.com/cgi-bin/main.plex